BioMarin Pharmaceutical Inc.
As of Oct 22, 2026, BioMarin Pharmaceutical is in Stage 3, the topping phase, now in week 2 (since Oct 14, 2026). It closed at $56.63, 19.4% below its 52-week high and below its 200-day average, which is falling.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Eur… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BMRN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BMRN among Biotechnology164th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …164 | BMRN | Stage 3 · wk 2 | 59 | −9.0% |
BioMarin Pharmaceutical: quick answers
What stage is BioMarin Pharmaceutical in?
As of Oct 22, 2026, BioMarin Pharmaceutical (BMRN) is in Stage 3, the topping phase. It entered Stage 3 on Oct 14, 2026 and is in week 2. What the four stages mean
Is BioMarin Pharmaceutical in an uptrend?
Its uptrend has stalled. BioMarin Pharmaceutical is in Stage 3, the topping phase that follows an advance. It trades 3.2% below its 200-day average, which is falling.
How far is BioMarin Pharmaceutical from its 52-week high?
BioMarin Pharmaceutical closed at $56.63 on Oct 22, 2026, 19.4% below its 52-week high of $70.24. Its 52-week low is $49.67.
How has BioMarin Pharmaceutical performed over the past year?
As of Oct 22, 2026, BioMarin Pharmaceutical is up 5.2% over the past year and down 4.7% so far in 2026.
Which sector and industry is BioMarin Pharmaceutical in?
BioMarin Pharmaceutical is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.